Polysubstance addiction vulnerability in mental illness: Concurrent alcohol and nicotine self‐administration in the neurodevelopmental hippocampal lesion rat model of schizophrenia by Sentir, Alena et al.
Polysubstance addiction vulnerability in mental illness: Concurrent 
alcohol and nicotine self-administration in the neurodevelopmental 
hippocampal lesion rat model of schizophrenia  
Running Title: Co-addictions in NVHLs 
 2nd Submit to Addiction Biology 10/25/2018 
Alena Sentir, BS 1,2          asentir@iupui.edu 
Richard L Bell, PhD 1        ribell@iupui.edu 
Eric A. Engleman, PhD1      eenglema@iupui.edu 
*R. Andrew Chambers, MD1,2    robchamb@iupui.edu
1Department of Psychiatry, Indiana University School of Medicine, Indianapolis  
2Laboratory for Translational Neuroscience of Dual Diagnosis & Development, IU Neuroscience 
Research Center 
*Corresponding Author:
R. Andrew Chambers, M.D.
Associate Professor of Psychiatry
Director, Laboratory for Translational Neuroscience of Dual Diagnosis & Development
Director, Addiction Psychiatry Training Program
Indiana University School of Medicine
IU Neuroscience Research Center
Suite 314
320 West 15th Street, Indianapolis, IN, 46202
W: (317) 278-1716
Email: robchamb@iupui.edu
Abstract: 250 words (250) 
Introduction: 722 
Methods: 1254 
Results: 1048 
Discussion: 1734 
Overall length:  4763 (5000) 
References: 49 
Figures: 8 
Tables: 0 
Supplementary Material: 0 
____________________________________________________
This is the author's manuscript of the article published in final edited form as: 
Sentir, AM, Bell, RL, Engleman, EA, Chambers, RA (2018) “Polysubstance addiction vulnerability in mental illness: 
concurrent alcohol and nicotine self-administration in the neurodevelopmental hippocampal lesion rat model of 
schizophrenia” Addiction Biology;1-10. https://doi.org/10.1111/adb.12704
2 
 
ABSTRACT  
Multiple addictions frequently occur in patients with mental illness.  However, basic research on 
the brain-based linkages between these comorbidities is extremely limited.  Toward 
characterizing the first animal modeling of polysubstance use and addiction vulnerability in 
schizophrenia, adolescent rats with neonatal ventral hippocampal lesions (NVHLs) and controls 
had 19 weekdays of 1 hour/day free-access to alcohol/sucrose solutions (fading from 10% 
sucrose to 10% alcohol/2% sucrose on day 10)  during post-natal days (PD 35-60).  Starting in 
adulthood (PD 63), rats acquired lever pressing for concurrent oral alcohol (10% with 2% 
sucrose) and iv nicotine (0.015 mg/kg/injection) across 15 sessions.  Subsequently, 10 operant 
extinction sessions and 3 reinstatement sessions examined drug-seeking upon withholding of 
nicotine, then both nicotine and alcohol, then reintroduction. Adolescent alcohol consumption 
did not differ between NVHLs and controls.  However, in adulthood, NVHLs showed increased 
lever pressing at alcohol and nicotine levers that progressed more strongly at the nicotine lever, 
even as most pressing by both groups was at the alcohol lever.  In extinction, both groups 
showed expected declines in effort as drugs were withheld, but NVHLs persisted with greater 
pressing at both alcohol and nicotine levers.  In reinstatement, alcohol re-access increased 
pressing, with NVHLs showing greater nicotine lever activity overall.  Developmental temporal-
limbic abnormalities that produce mental illness can thus generate adult poly-drug addiction 
vulnerability as a mechanism independent from putative cross-sensitization effects between 
addictive drugs.   Further pre-clinical modeling of 3rd order (and higher) addiction-mental illness 
comorbidities may advance our understanding and treatment of these complex, yet common 
brain illnesses.  
Keywords: addiction, alcohol, comorbidity, mental illness, neurodevelopmental, nicotine 
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INTRODUCTION 
Complex comorbidities of psychiatric illness and substance use disorders are mainstream 
brain health conditions, frequently involving serious illnesses such as schizophrenia where about 
half of patients have alcohol and/or illicit substance disorders, and more than 75% are nicotine-
addicted (Dixon, 1999; Morisano et al., 2009; Mueser et al., 1992; O Brien et al., 2004; Regier et 
al., 1990).  Although often termed ‘dual diagnosis’ implying comorbidity of just 2 disorders (i.e. 
one mental illness and one addiction), many dual diagnosis cases involve higher order 
combinations of multiple addictions with one or more mental illnesses (Barnett et al., 2007; 
Lambert et al., 2005; Sajid et al., 2016).  These ‘high order’ dual diagnosis cases represent 
significant treatment challenges not only because these patients are sicker, but because 
behavioral health care remains largely fragmented into segregated mental health vs. addiction 
services that are unable to provide integrated care (Balhara et al., 2016; Chambers et al., 2010a; 
Schmidt et al., 2011).  
To advance prevention and treatment of 3rd (and higher) order dual diagnosis conditions, 
more research is needed to better understand and counteract biological mechanisms that link 
severe mental illnesses like schizophrenia and poly-addiction vulnerability (Chambers, 2018; 
Chambers et al., 2001).  The present study pursues this goal pre-clinically by examining 
concurrent poly-substance self-administration in a widely studied and well-validated 
neurodevelopmental animal model of schizophrenia.  Specifically, we examined concurrent adult 
self-administration of both alcohol and nicotine in the neonatal ventral hippocampal lesion 
(NVHL) model, which is produced by delivery of axon-sparing neurotoxic lesions to 7-day old 
rat pups (Lipska et al., 1993).  Both alcohol and nicotine are commonly used in the general 
population, and by schizophrenia patients in addictive patterns at rates at least 2 times greater 
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than in the general population (DiFranza and Guerrera, 1990; Falk et al., 2006; Kandel et al., 
1997; Lasser et al., 2000).   Thus, our study design provides a first animal modelling approach to 
a commonly encountered mental illness/poly-substance combination that allows for 
measurement of multi-drug-addiction vulnerability in the context of concurrent poly-drug use.       
   The applicability of the NVHL model in this approach is suggested by an accumulation 
of over 100 studies characterizing the mental illness and/or the addiction vulnerability features of 
the model (Tseng et al., 2009).  NVHLs generate a developmentally progressive syndrome that 
encompasses cognitive and negative symptom domains of human schizophrenia with positive-
range symptoms that worsen after adolescence (Tseng et al., 2009).  The model also produces 
frontal cortical-striatal-limbic circuit dysfunction, that mimics core histopathological, 
neuroimaging, and neurochemical features schizophrenia, including markers of prefrontal 
dysfunction (i.e. ‘hypofrontality’) and striatal network hypersensitivity to the effects of 
mesolimbic dopamine release (Chambers et al., 2013; Chambers et al., 2010b; Chambers et al., 
2010c; O'Donnell, 2012; Tseng et al., 2009; Tseng et al., 2007).   
These same biological attributes likely underpin impairments of decision-making and 
impulse control in the NVHL model that emulate human endophenotypes of addiction 
vulnerability measured before drug exposure (Chambers et al., 2005; Placek et al., 2013; Rao et 
al., 2016).  With drug exposure, NVHLs show acceleration/amplification of the addictive disease 
process in a non-drug specific way as measured by both experimenter delivered (i.e. behavioral 
sensitization) to cocaine, alcohol or nicotine (Berg and Chambers, 2008; Chambers and Taylor, 
2004; Conroy et al., 2007)  and self- administration (i.e. instrumental learning reinforcement) to 
all of these same 3 drugs (Berg et al., 2011; Berg et al., 2014; Chambers and Self, 2002; 
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Jeanblanc et al., 2015; Karlsson et al., 2013; Khokhar and Todd, 2018)  and methamphetamine 
(Brady et al., 2008).     
This present study is the first to compare NVHL vs. SHAM-operated (healthy) rats in the 
acquisition of instrumental responding for any two drugs (in this case alcohol and nicotine) self-
administered concurrently, followed by tests of drug-seeking during extinction and drug-induced 
relapse.  To increase the likelihood that rats would concurrently self-administer both drugs in 
adulthood, our design was informed by the capacity of adolescent drug exposure to enhance 
adult addiction risk (Chambers et al., 2003).  Specifically, given our estimation that the rats 
might be slower to acquire operant responding for access to oral alcohol compared to iv nicotine 
delivery, and given prior work by Jeanblanc et al, showing that adult alcohol consumption is 
amplified in NVHL rats after adolescent alcohol drinking (Jeanblanc et al., 2015), we first 
exposed both NVHL and SHAM rats to free-access alcohol drinking during adolescence, 
followed by concurrent instrumental operant acquisition to both alcohol and nicotine in 
adulthood.        
METHODS  
Subjects and Neonatal Surgeries 
Sprague Dawley litters born from rats arriving 14-17 days gestation (Harlan, 
Indianapolis) were culled to males on post-natal day (PD)-3 in preparation for surgeries on PD-7. 
Thirty-six pups weighing 16-19g were randomized evenly to NVHL or SHAM surgeries as 
detailed in (Chambers and Lipska, 2011).  Briefly, ibotenic acid  (3.0 µg; Sigma) in 0.3 µL 
artificial CSF (or aCSF only for SHAMs) was delivered under hypothermic anesthesia via 
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infusion into the ventral hippocampus bilaterally (A/P - 3.0 mm, M/L ± 3.5 mm, DV -5.0 mm 
from bregma).  Pups were reared under standard conditions until weaning (PD-21), then housed 
in lesion-like pairs until adulthood, when they were individually housed following jugular 
venous catheterization.  Surgical and experimental procedures (Figure 1) were conducted in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals and Indiana 
University IACUC-approved protocols.  
Drug preparation and adolescent alcohol exposure 
Nicotine hydrogen tartrate salt (Sigma) was dissolved in 0.9% normal saline to a stock solution 
of 0.25 mg/ml free base and adjusted to pH of 7.4 (Matta et al., 2007). For iv self-administration, 
doses were prepared daily on a per rat basis from stock to achieve 0.015 mg/kg/infusion. Stock 
also provided subcutaneous injections at a volume of 1ml/kg during reinstatement. 
Sucrose/alcohol solutions were prepared for the adolescent pre-exposure and adult self-
administration experiments as delivered via sipper tube or trough/mechanical dipper, 
respectively.  The pre-exposure sucrose/alcohol fade was based on protocols in (Czachowski et 
al., 1999) and (Berg et al., 2011) which reliably produce alcohol consumption leading to a final 
solution that has carbohydrate and alcohol concentrations comparable to human alcoholic 
beverages. Over 19 days, adolescent rats had access to the following: 3 days of 10% sucrose;  2 
days of 10% Sucrose/2% ETOH (10s/2e); 2 days of 10s/5e, 1 day of 10s/10e; 1 day of 5s/10e;  
then 2s/10e for 10 more sessions.  This regimen was delivered over a 4-week (Monday-Friday) 
schedule (PD-35-60), except for on the 4th Monday (PD 56) when rats underwent iv 
catheterization surgeries.  Rats had access to these solutions (via sipper tubes) for 1 hour/day in 
Plexiglas cages away from their home cages. 
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Jugular Catheterization Surgery 
On PD-56, subjects underwent jugular venous catheterization as described previously (Chambers 
and Self, 2002), with Silastic tubing (Dow Corning, Midland, MI) threaded into the right jugular 
vein coursing subcutaneously over the shoulder to exit the back via 22-gauge cannula (Plastics 
One, Roanoke, VA).  To maintain patency, catheters were flushed before and after operant 
sessions and once daily on weekends with 0.3 ml of 20 u/ml heparinized saline containing 0.13 
mg/ml gentamicin.  Patency was verified after Friday operant sessions by pushing 0.1mg/0.1ml 
iv of methohexital sodium (McKesson, USA) which produces a brief loss of consciousness.  Rats 
with failed or infected catheters were excluded from the experiment.  
 
Operant Co-Self-Administration of Oral Alcohol and IV Nicotine 
Concurrent self-administration was conducted in Med Associates chambers (St. Albans, VT) 
interfaced with Med PC software that controlled lighting and drug deliveries while recording 
instrumental activity.  Our eight units, modified specifically for concurrent instrumental delivery 
of alcohol and nicotine (as in simulation of the traditional ‘Pub’) were termed ‘Pub-Med’ and 
equipped with 3 non-retractable levers across the right wall of the chamber with only a house 
light on the opposing (left) wall.  The 1st lever (left most, from the rat’s perspective) activated a 
magazine with a 0.1ml dipper cup that retrieved 2s/10e solution from a trough; the 2nd lever 
(middle, ‘blank’) was completely inactive; the 3rd lever (rightmost) initiated an iv infusion that 
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delivered 0.015mg/kg of nicotine.  Cue lights were positioned above the levers and the magazine 
delivering the alcohol dipper (located between alcohol and blank levers). 
Self-administration sessions in ‘Pub Med’ began on PD-63 for 5 days/week (M-F) for 7 
and a half weeks.  To promote exploratory behavior for the operant procedure, rats were food 
deprived 24 hours preceding the first operant session and remained food restricted to greater than 
85% of PD-63 body weight with delivery of 2-3 pellets daily of rat chow after sessions through 
the acquisition phase.   Over this 3-week phase (15 x 1 hour sessions), both drug-paired levers 
delivered reinforcers on an FR1 schedule.  The house light was on for the duration of the 
sessions.  Presses on the alcohol lever activated the cue lights above the lever and the magazine 
for the 10-second dipper presentation bearing 2s/10e solution.  Presses on the alcohol lever 
during this 10-second interval had no consequences and were recorded as time out presses.  
Active presses on the nicotine lever delivered a 0.015 mg/kg/infusion over 3 seconds followed 
by a 7 second time out phase.  The cue light above the nicotine lever was on for 10 seconds 
including during the infusion and time out phase; more nicotine lever presses during this phase 
had no consequences but were recorded as time out presses.  Presses on the middle ‘blank’ lever 
were also recorded.  All levers were able to operate independently and both drugs could be 
consumed simultaneously or in any back and forth pattern.  Cue lights and software 
programming remained consistent through all phases of self-administration (Figure 1) including 
acquisition (sessions 1-15), nicotine-only extinction when 2s/10e was still available (sessions 16-
20), during extinction from both nicotine and alcohol (sessions 21-25); and over 3 sessions of 
reinstatement (sessions 26-28).  Although it would have been informative to extinguish either 
nicotine or alcohol first, we chose nicotine first, since the drug (being delivered iv) was likely 
more reinforcing than the alcohol.  Tail bloods were collected 30+/-10 minutes of the sessions on 
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Fridays of week 1 and 2 (sessions 5 and 10) of acquisition to confirm alcohol consumption.  Rats 
were given a week off from ‘Pub Med’ testing after both the nicotine and nicotine/alcohol 
extinction phases.  For reinstatement, on session 26, rats were given a 1 ml/kg subcutaneous 
injection of saline 30 minutes prior to the start of the session.  On session 27, rats were given a 
0.25 mg/kg sc nicotine injection 30 minutes prior.  For the last session, rats were again given 
nicotine 30 minutes prior and troughs were filled with 2s/10e.  
Histological Lesion Verification 
Following Pub Med sessions and sacrifice, brains were removed whole and cryostat cut into 40 
µM coronal sections through the rostral-caudal extent of the hippocampus.  Mounted sections 
were fixed and 0.5% thionin stained.  Microscopic examination of both lesioned and SHAM 
brains were performed blind to behavioral data.  Rats showing bilateral evidence of atrophy, 
paucity of nuclei, and cellular disarray in the ventral hippocampus with some lateral ventricular 
enlargement, were included.  Brains with unilateral damage, dorsal hippocampal damage or 
direct damage encompassing structures adjacent to the ventral hippocampus were excluded from 
the study (Chambers and Lipska, 2011).  Five lesioned rats were excluded yielding final totals of 
13 NVHL and 18 SHAMS rats (Figure 2).  
Data Analysis 
Analyses of adolescent drinking and adult self-administration data generally utilized mixed 
model repeated measures ANOVAs with lesion status as the main independent factor and alcohol 
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consumption or bar pressing as dependent variables. Adolescent drinking (10 sessions at the 
2s/10e concentration), adult acquisition (15 sessions), nicotine extinction (5 sessions), alcohol & 
nicotine extinction (5 sessions) and reinstatement (3 sessions) were each examined 
independently with separate analyses on each lever.  Active presses, and time out or total presses 
were analyzed separately.  For acquisition sessions, simple post-hoc t-tests where applied to 
compare NVHL vs. SHAM pressing on each day to assist with interpretation of the initial 
ANOVAs that revealed simple lesion or lesion x day interactions.  All significant statistical 
results (assumed at p<0.05), and informative negative results are reported with group means + 
SEMS throughout. 
RESULTS 
Adolescent Drinking and Adult Acquisition of Co-Self-Administration 
Across the final 10 weekday sessions of adolescent drinking (PD 46-60) at the 2s/10e 
concentration, rats significantly increased their consumption (day: F(9,261)=6.3, p<0.001) so 
that alcohol intake increased from 0.13+0.03 gm ETOH/kg rat on day 1 to 0.47+0.08 g/kg on day 
10. There was no lesion based difference in consumption (lesion: F (1, 29)=0.8, NS), or lesion x
day interaction (F(9,261)=0.8, NS). 
 Over the 15 concurrent alcohol (2s/10e)/nicotine acquisition sessions, active presses on 
the alcohol lever (Figure 3A) increased for all animals (day: F(14, 406)=10.1, p<0.00), with 
NVHLs showing greater active pressing (lesion: F(1,29)=7.7, p<0.01) but no lesion x day 
interaction F(14, 406)=0.7, NS), even as  NVHL and SHAMs showed the same level of active 
presses on session 1.  Time out responding on the alcohol lever (Figure 3B) also increased then 
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stabilized over the 15 sessions (day: F(14,406)=6.6, p<0.001), but there were no lesion 
(F(1,29)=1.9, NS) or lesion x day interaction (F(14, 406)=0.6, NS).   To confirm that animals 
were actually drinking alcohol presented to them via active alcohol lever presses, tail blood 
alcohol levels were analyzed using linear regressions between the number of dipper presentations 
(x-variable) and tail blood alcohol levels (y-variable).  After the 5th session, 12 NVHL and 13 
SHAM rats yielded adequate blood samples showing a significant linear relationship 
((F(1,24)=16.8, p<0.001); R=0.65; y= 0.69x +5.2) (Figure 4A).  After the 10th session, a better 
yield of tail bloods from all 13 NVHL and 18 SHAMs also showed a significant relationship 
between blood alcohol levels and active alcohol lever presses ((F(1,30)=6.9, p<0.05); R=0.44; 
y=0.35x+6.3) (Figure 4B).   
 Active nicotine lever presses also increased steadily over the 15 acquisition sessions (day: 
F(14,406)=16.5, p<0.001), after NVHL and SHAM rats started out at similar low levels on day 1 
(Figure 3C).  NVHLs also showed greater overall active nicotine lever presses (lesion: 
F(1,29)=10.9, p<0.01) with a significant day x lesion interaction (F(14,406)=2.2, p<0.01) that, as 
suggested by simple post-hoc comparisons on each day, was generated by a progressive 
widening of group differences expressed over the final 8 sessions.  Time out responding on the 
nicotine lever showed similar patterns but with less statistical strength in terms of group 
differences (Figure 3D) with overall increases in pressing (day: F(14, 406)=5.3, p<0.001), where 
NVHLs produced more presses overall (lesion: F(1,29)=7.7, p<0.05) and in a significant lesion x 
day interaction (F(14,406)=1.8, p<0.05). 
Analysis of responding on the blank lever (Figure 3E) also showed more subtle but still 
significant increases in lever responding for all rats across the 15 sessions (day: F(14,406)=2.7, 
p<0.001).  There was also greater NVHL pressing (lesion: F(1, 29)=5.7, p<0.05) without the day 
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x lesion interaction (F(14, 406)=1.1, NS) on the blank lever.   Examination of the fractions of 
total activity directed at each lever (Figure 5) shows that relative levels of responding evolved 
on all three levers (alcohol (days: F(14,406)=8.7, p<0.001) , nicotine (day: (F(14,406)=3.0, 
p<0.001) blank (F(14,406)=5.6, p<0.001)) with the proportion of alcohol responding growing 
faster than nicotine responding over the first five days, then stabilizing at about 2:1 ratios 
(alcohol to nicotine) over days 5-15 with blank lever pressing being relatively extinguished.  
NVHLs did not differ from SHAMs in overall proportions of type of lever responses but did 
show a significant growth in the relative proportion of presses at the nicotine lever (day x lesion: 
F(14,406)=1.9, p<0.05).    
  
Single and Poly-Drug Extinction 
In sessions 16-20 with nicotine but not alcohol delivery withheld, there was no overall 
change in alcohol lever responding examined as active presses (Figure 6A; day: F(4, 116)=1.0, 
NS), or total alcohol lever presses (active + time out hits are examined  for better comparison to 
total nicotine lever presses, which has no active vs. time out component) (Figure 6B; day: 
F(4,116)=0.7, NS)). However, NVHLs continued to show greater alcohol lever responding for 
both active (lesion: F (1, 29)=6.6, p<0.05) and total presses (F(1, 29)= 6.3, p<0.05).  In contrast, 
there was a significant decline in total lever pressing on the nicotine lever (Figure 6C) consistent 
with extinction (day: F(4, 116)=8.1, p<0.001) while NVHL rats continued to press for nicotine to 
a greater extent (lesion: F(1,29)=11.1, p<0.01) than SHAMs across these sessions, without a day 
x lesion interaction (F(4,116)=0.8, NS)).   
In sessions 21-25, with delivery of both alcohol and nicotine denied, total alcohol lever 
pressing (Figure 7A) declined significantly consistent with extinction (day: F(4, 116)= 19.2, 
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p<0.001), while NVHL rats persisted in pressing for ETOH at greater rates than SHAMs (lesion: 
F(1,29)=4.6, p<0.05) without a day x lesion interaction: F(4,116)=0.4, NS).  On the nicotine 
lever (Figure 7B), in continuation of patterns observed in the prior nicotine-only extinction-
sessions (Figure 6)  rats continued to show ongoing declines in total pressing (day: F(4, 
116)=13.5, p<0.001), with NVHL rats still pressing more for nicotine overall (lesion: F(1,29): 
5.4, p<0.05; day x lesion : F(4,116)=0.28, NS).   Analysis of blank lever pressing during the final 
5 extinction sessions showed ongoing declines in low level pressing (day: F(4,116)=3.3, p<0.05; 
means of all rats from 7.4+1.0 presses/hr (session 21) to 4.5 +1.2 presses/hr (session 25), with no 
differences based on lesion (lesion: F(4, 29)=1.7, NS; day x lesion: F(4,116)=0.45, NS).  This 
blank lever pressing differed from blank lever pressing when ETOH was still being delivered 
during nicotine-only extinction (sessions 16-20). Over these sessions, although overall blank 
lever responding was also quite low and still extinguishing (day: F(4,116)=4.9, P<0.01), NVHL 
rats were pressing more (lesion: F(1,29)=14.4p<0.01) and showed steeper overall declines in 
responding (day x lesion: F(4,116)=2.7, p<.05), such that NVHLs declined from 9.9+2.2  
presses/hr (session 16) to 4.0+0.8 presses/hr (session 20), compared to SHAMs with 3.8+0.8  
(session 16 ) and 2.5+0.7 presses/hr (session 20).    
Single and Poly-Drug Re-instatement of Drug Seeking 
  Across all 3 reinstatement sessions (Figure 8)  there was no change in blank lever 
pressing (day: F(2,58)=2.5, NS) or lesion-based differences in blank lever pressing (lesion: 
F(1,29)=1.8, NS; day x lesion: F(2,58)=1.8, NS).   However, there was an overall increase in 
total lever pressing on the alcohol lever (day: F(2,58)=26.5, p<0.001) as expected, with 
substantial increases when alcohol became available on day 3. These changes were not 
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accompanied by lesion-based differences in alcohol lever presses (lesion: F(1,29)=0.07, NS; day 
x lesion: F(2,58)=2.9, NS).   On the nicotine lever, NVHLs continued to press more (lesion: 
F(1,29)=17, P<0.001), without substantial increases across sessions overall (day: F(2,58)=0.7, 
NS) or according to lesion status (day x lesion: F(2,58)=2.9, NS).  
DISCUSSION 
This study is to our knowledge the first to demonstrate concurrent instrumental oral 
alcohol and iv nicotine self-administration in a neurodevelopmental model of mental illness, and 
to show that addictive behaviors with respect to both drugs are simultaneously increased by the 
mental illness model.   Le et al  have previously show that healthy Wistar rats will concurrently 
self-administer oral alcohol and iv nicotine (Le et al., 2010), and that in Long Evans rats, initial 
self-administration of nicotine will enhance subsequent self-administration of alcohol (Le et al., 
2014).  The latter finding is consistent with a ‘cross-sensitization’ or ‘gateway effect’, whereby 
use of, or addiction to one drug biologically predisposes to addiction to one or several others via 
shared or synergistic pharmaco-biological effects (e.g. in the mesolimbic reward pathways) 
(Nestler, 2005).  While providing a compelling explanation for the occurrence of polysubstance 
use disorders, e.g. where rates of nicotine addiction are 2-3 fold higher in patients with 
alcoholism, than in the general population (Falk et al., 2006), the present findings are among the 
first to suggest an additional causal dynamic: The co-occurrence of 2 drugs used in addictive 
patterns may be caused by their shared vulnerability or ‘gravitation’ toward a third pathological 
entity—the mental illness.  This possibility has been preliminarily supported by prior work in the 
NVHL model showing that it confers elevated addiction vulnerability to both nicotine and 
alcohol, completely independently of one another (Berg et al., 2011; Berg et al., 2014; Jeanblanc 
15 
 
et al., 2015), whereas the present study confirms it in the context of concurrent self-
administration of both drugs. 
   It is possible that both the cross-sensitization effect and mental illness-induced 
vulnerability to addiction may simultaneously, biologically attract all these pathologies together 
causing high-order dual diagnosis cases that are now routinely encountered in behavioral health 
care settings (Sajid et al., 2016).  Notably, the present study does not rule out the possibility that 
a cross-sensitization effect between alcohol and nicotine was also in play, nor was it designed to 
test which pathological attraction,  the ‘drug-drug’  or the ‘drug-mental illness’ one is greater.  
Future animal studies are needed to dissect and characterize the relative strengths of these causal 
dynamics, including the intriguing possibility that mental illness could biologically enhance 
drug-to-drug sensitization.  The majority of work looking at how the NVHL model biologically 
worsens the addiction process has been limited to cocaine.  These studies have shown that while 
the NVHL model does not increase drug-induced DA release into the ventral striatum as 
compared to healthy animals (Chambers et al., 2010c), the cumulative neuroplastic and 
behavioral effects of drug-induced DA release are accentuated by abnormal neuronal activity 
(Chambers et al., 2010b) and gene expression patterns (Chambers et al., 2013) present in both 
the prefrontal cortex and dorsal striatum of NVHL rats.  So, to the extent that alcohol and 
nicotine both exert cocaine-like reinforcing effects in schizophrenia (Berg et al., 2014; D'Souza 
et al., 2006) via their shared effects on increasing meso-striatal DA transmission, it is plausible to 
speculate that both their independent and synergistic (e.g. drug-drug sensitizing) neuroplastic 
effects may be expressed and amplified by the NVHL model—post-synaptic to DA transmission 
within prefrontal cortex and striatal networks.   Consistent with this, GABAergic-interneuron 
control of prefrontal cortical networks (e.g. required for adult-age capacities for working 
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memory and impulse control), requires proper maturation during adolescence, and is modulated 
by meso-cortical DA afferents (Caballero and Tseng, 2016; Lew and Tseng, 2014).  NVHLs 
disrupt the development of these complex regulatory interactions leading to impaired DA 
modulation of prefrontal GABAergic interneurons in adulthood, and other physiological signs of 
cortical incoherency in which both GABA and glutamatergic neurons are implicated (Tseng et 
al., 2008; Tseng et al., 2007; Vohs et al., 2012).  Given evidence presented here and in prior 
studies that addiction vulnerability of NVHLs is more fully expressed after adolescence, and 
correlates with deficits of working memory and impulse control (Berg et al., 2014; Rao et al., 
2016) a complex array of disruptions of information processing and neuroplasticity involving 
both excitatory and inhibitory neurotransmission within cortical-striatal networks likely 
contribute to both mental illness symptoms and non-drug specific susceptibility to addiction.      
 A key design feature of the present study is that rats had a free-access drinking regimen 
of a sucrose/alcohol solution during adolescence as informed by Jeanblanc et al, to increase the 
likely-hood of successful acquisition of concurrent instrumental self-administration of both drugs 
in adulthood (Chambers et al., 2003; Jeanblanc et al., 2015). This approach was also undertaken 
to help avoid the possibility that heavy use of one drug in the operant boxes could actually drive 
down use of another drug as has been observed under certain circumstances between alcohol and 
nicotine (Le et al., 2014) in healthy rats.  Our findings suggest our approach worked, while 
replicating prior findings showing that although the NVHL model does not cause increased 
alcohol-consumption during adolescence, the alcohol addiction vulnerability phenotype of 
NVHLS is expressed in adulthood (Jeanblanc et al., 2015).  Similarly, we have seen the same 
kind of effect with nicotine: behavioral sensitization to nicotine is not increased in adolescent 
NVHLs, although it is in adult NVHLs, who also show increased nicotine self-administration 
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compared to SHAMs, regardless of adolescent nicotine exposure  (Berg and Chambers, 2008; 
Berg et al., 2014).   Notably, because all rats were exposed to alcohol solutions in adolescence, 
this study was not able to determine if this exposure was necessary for, or caused differential 
expression of the adult NVHL vs SHAM phenotypes.   
The use of a three-lever system in the present experiments with one blank lever, and 
time-out phases on both the alcohol and nicotine levers, allowed us to examine NVHL-model 
differences in the specificity of drug pursuit and effort.  During acquisition, NVHL-based 
differences from SHAMs were greater for active lever as compared to time-out responding with 
respect to both drugs, and, as compared to blank lever hitting. These patterns indicate that 
NVHLs specifically increased pressing that was most certain to deliver drug, but simultaneously 
some degree of NVHL-induced non-specific over-flow of pressing (on the nicotine time-out and 
blank lever) did occur.  Even so, this non-specific pressing in NVHLs was strongest for nicotine-
lever time-out responding, which emerged in the last half of the acquisition series when nicotine 
intake reached the greatest levels, whereas NVHL difference in blank hitting became more 
infrequent with more sessions.   
The behavioral economy of overall lever responding was remarkably similar between the 
groups with rats settling into patterns by day 4 of acquisition where 50% to 75% of all presses 
were on the alcohol lever, 20% to 40% were on the nicotine lever and <10% were on the blank 
lever.  It is not entirely clear why the alcohol lever was pressed more frequently than the nicotine 
lever overall for both active and time out presses, although active nicotine presses were 
guaranteed to deliver a  3-second iv infusion, whereas active alcohol lever presses just presented 
the cup of alcohol, still requiring the animal to find and drink from it.  This difference may have 
produced more relative effort to access the alcohol.  Also, since all rats were already experienced 
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with alcohol (in adolescence) but not nicotine, they may have already been more motivationally 
sensitized to alcohol compared to nicotine.  Notably, in anecdotal observation through viewers 
into the chambers on the first acquisition day, we saw rats immediately maneuvering to the 
trough where the alcohol was available, presumably drawn by alcohol odor cues.  Despite all 
this, NVHL rats did show a significant growth in the percentage of activity on the nicotine lever 
compared to SHAMs (but not on the other levers), which led to more robust NVHL-nicotine 
findings in the extinction and reinstatement sessions.  
Over the first extinction series, where nicotine (but not alcohol)  delivery was denied, 
group differences between NVHLs and SHAMs were statistically more significant on the 
nicotine (p<0.01) compared to alcohol lever (p<0.05), while significant between session declines 
in responding were only seen on the nicotine lever. Then, during the next extinction series when 
both drugs were denied, significant declines in both levers were obtained, with the NVHL rats 
maintaining increased efforts on both levers.  During re-instatement, NVHL activity on the 
nicotine lever was exclusively higher (compared to the other levers) pervasively across sessions, 
whereas return of alcohol access significantly boosted alcohol lever activity for all rats regardless 
of lesions status.  Somewhat unexpectedly, nicotine injections introduced in the second 
reinstatement session did not significantly increase nicotine lever responding compared to levels 
on the first (saline injection day).  It is possible that the nicotine dose used (0.25mg/kg/sc) was 
not high enough to elicit a strong reinstatement response specific to NVHLS as we’ve seen by 
using a 0.5mg/kg dose reported previously (Rao et al., 2016).  In any event, the acquisition, 
extinction and reinstatement data collectively suggest that in the context of the adolescent 
alcohol pre-exposure, the adult addiction vulnerability phenotype expressed in the NVHL model 
is generalizable to both alcohol and nicotine but occurs with greater robustness with nicotine.  
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This interpretation should be qualified by the fact that the alcohol in this paradigm had to be 
orally consumed, whereas the nicotine was iv injected. This difference created reliability, work-
load and  pharmacokinetic differences for the animals in terms of how the 2 drugs arrived in their 
brains, which all could be assumed to decrease the relative addictive potential of alcohol 
compared to nicotine in this paradigm.  Moreover, it is generally accepted that nicotine is 
relatively more addictive than alcohol, and so our findings are interpretable as indicating that 
NVHLs increase addiction risk in a way that is more readily expressed with more addictive 
drugs.   
 In summary, the present findings, while representing at least the 2nd published replication 
showing increased addiction vulnerability to either nicotine  (Berg et al., 2014; Rao et al., 2016) 
or alcohol (Berg et al., 2011; Jeanblanc et al., 2015; Khokhar and Todd, 2018) in the NVHL 
model, are the first to show the comorbidity of these addiction vulnerability phenotypes when 
both drugs are used concurrently.  A huge variety of alternative study designs may be pursued 
based on the mental illness/poly-addiction model approach described here to investigate the 
interactive pathologies of these conditions on neurobiology, cognition and motivation. While 
providing a platform to pre-clinically investigate novel preventative and treatment approaches 
for 3rd and higher order dual diagnosis patients, these findings point to a fundamental connection 
between mental illness and multiple addictions that should translate clinically to greater 
integration of  professional training, treatment and research on these complex comorbidities 
(Barnett et al., 2007; Chambers, 2018).       
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FIGURE LEGENDS 
Figure 1.  Surgical and experimental timeline.  
Figure 2.  Brain mapping of lesion extent. Maps on left show the range of lesion impact across 
all N=13 NVHL rats included in the study at sections AP relative to Bregma (Maps adapted 
from Swanson, LW (2004) Brain Maps: Structure of the Rat Bain, 3rd ed., New York, 
Elsevier).  Largest extent of lesions in the group are shown in black with smallest lesions 
shown as white insets (e.g. at -5.00).   Right column micrographs show a medium-sized 
lesion in the NVHL group vs. a SHAM rat.   
Figure 3.  Acquisition of concurrent instrumental self-administration of oral alcohol and iv 
nicotine.  (A) Active alcohol (ETOH) lever hits presenting access to 0.1 ml 2s/10e solution 
were greater in NVHL rats (**), (B) with no group differences in Time Out (T.O.) 
responding on the alcohol lever.  On the nicotine (NIC) lever, (C) active hits delivering 0.015 
mg/kg nicotine were greater in NVHL rats (**), accompanied by greater across-sessions 
growth of lever pressing in NVHLs (** day x lesion). (D) T.O. responding on the NIC lever 
was also greater in NVHLs overall and in term of lesion specific growth but with less 
statistical strength (*). (E)  Blank lever hits were also elevated in NVHLs overall (*) but with 
less strength than at alcohol and nicotine levers, and with no day x lesion interaction.  All 
bars reflect means + SEMS with asterisks above bars representing simple t-test comparisons 
by lesion status on that day. All asterisks represent degree of statistical significance 
(*p<0.05; **p<0.01; ***p< 0.001). 
Figure 4.  Linear correlations between active ETOH lever pressing (cups presenting 0.1ml of 
2s/10e solution) and tail blood alcohol levels collected 30 +/-10 minutes after sessions on 
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Fridays of week 1 and 2 (sessions 5 and 10). After session 5 (A) adequate samples were 
drawn from n=25 rats yielding a significant liner correlation (F(1,24)=16.8, p<0.001), and 
after session 10 (B) all 31 rats yielded a significant correlation (F(1,30)=6.9, p<0.05).  
Figure 5.  Re-examination of acquisition responding as relative fractions of activity on alcohol 
vs. nicotine vs. blank levers. The fractions of total pressing evolved highly significantly on 
all 3 levers (***day), settling into 6:3:1 ratios (ETOH: NIC: BLANK) by day 5.  There was 
no overall group difference in preference for lever, although NVHLs showed a significant 
time progression of responding preference on the nicotine lever (*day x lesion).   All bars 
reflect means + SEMS; (*p<0.05; ***p< 0.001). 
Figure 6.  Extinction from nicotine only with continuation of alcohol access.  NVHL rats 
continued to press more frequently on the ETOH lever (*) in terms of both active (A) and 
total (active + T.O.) hits (B). Meanwhile, overall responding extinguished on the NIC lever 
(***day) but with NVHL rats continuing to press for nicotine (**).  All bars reflect means + 
SEMS; (*p<0.05; **p<0.01; ***p< 0.001). 
Figure 7. Extinction from nicotine and alcohol access.  (A) Total hits on the ETOH lever 
declined relatively precipitously (***day) compared to (B) on the NIC lever (*day) which 
had already been largely extinguished. NVHLs continuing to press more overall on both 
ETOH and NIC levers (*).  All bars reflect means + SEMS; (*p<0.05; ***p< 0.001). 
Figure 8.  Nicotine and alcohol reinstatement sessions. No lesion based differences emerged on 
the blank lever, regardless of saline (SAL) vs. nicotine (NIC) pre-injection condition vs. 
return of alcohol access with nicotine pre-injections (NIC).  Pressing on the ETOH lever 
increased strongly (***day) with return of alcohol access but not differentially so by lesion. 
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NVHLs persisted in showing increased activity on the NIC lever (***lesion) regardless of 
reinstatement condition. All bars reflect means + SEMS; (***p< 0.001).  
